Grail Inc Stock Price, News & Analysis

GRAIL announced initial results from the REFLECTION study evaluating the Galleri® multi-cancer early detection (MCED) test in veterans. The study, conducted across seven VA sites, showed a cancer signal detection rate of 1.30% (37/2854 participants) among veterans with toxic exposure, consistent with other populations. Of 28 participants completing 180-day follow-up, 12 cancer diagnoses were confirmed, with over half identified at early stages (I-III). The test demonstrated a positive predictive value of 42.9%. The study included veterans aged ≥22 years (mean age 60), with 70% exposed to toxic hazards during service. Lung cancer was the most common cancer signal detected.

GRAIL, Inc. (Nasdaq: GRAL) has announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Krevans will serve on the Board's Audit, Compensation, and Nominating and Governance Committees. With her addition, the Board now consists of five directors, four of whom are independent.

Krevans served as president and CEO of Sutter Health from 2016 to 2022, overseeing an integrated network of 14,000 clinicians, 24 hospitals, and various healthcare services. Her leadership focused on advancing clinical programs, innovation, and digital health to improve patient accessibility.

Bob Ragusa, CEO of GRAIL, expressed confidence in Krevans' ability to bring valuable experience to GRAIL's mission of establishing a new standard for multi-cancer early detection. Krevans' extensive healthcare background includes executive roles at Kaiser Permanente and in Maine's healthcare administration. She holds master's degrees in business administration and public health from UC Berkeley and has been recognized as one of the top healthcare leaders by Modern Healthcare.

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced the granting of equity awards to 55 recently hired non-executive employees. These awards, in the form of restricted stock units (RSUs) totaling 182,223 shares of GRAIL's common stock, were granted under the company's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs are designed to vest over approximately four years, with 25% vesting in either May or August 2025, depending on the employee's start date, and the remaining vesting annually thereafter. This vesting schedule is subject to continued employment with GRAIL or its subsidiaries.

GRAIL, Inc. (Nasdaq: GRAL) has published findings on the performance of its Galleri® multi-cancer early detection (MCED) test for prostate cancer in JCO Precision Oncology. The data, from the CCGA and PATHFINDER studies, show that Galleri preferentially detects aggressive, clinically significant prostate cancers over slow-growing cases.

Key findings include:

• 93% of detected prostate cancers were intermediate or high grade
• 67% were stage III or IV
• Cancer signal of origin prediction accuracy was >90%
• No low-grade cancers were detected
• Only 4.2% of stage I and II cancers were detected

These results suggest that Galleri could be valuable in population-based screening programs without contributing to overdiagnosis of indolent prostate cancers.

GRAIL, a healthcare company focused on early cancer detection, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will present on September 4, 2024, at 3:20 p.m. ET. Investors and interested parties can access both live and replay webcasts of the presentation through GRAIL's investor relations website at investors.grail.com. The webcast will remain available for replay for at least 30 days after the event, providing an opportunity for those unable to attend live to catch up on GRAIL's latest updates and insights.

GRAIL (Nasdaq: GRAL) reported Q2 2024 financial results, showing 43% year-over-year revenue growth to $32.0 million. The company faced a net loss of $1.59 billion, including a $1.42 billion goodwill and intangible impairment. GRAIL's adjusted gross profit increased 66% to $16.0 million, while adjusted EBITDA was $(139.4) million.

Key highlights include enrollment in the REACH study, completion of PATHFINDER 2 study enrollment, and final study visits for the NHS-Galleri trial. GRAIL announced a strategic restructuring, reducing headcount by 30% and focusing on core multi-cancer early detection priorities. These measures are expected to extend the company's cash runway into 2028 and reduce burn to $325 million in 2025.

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced it will release its second quarter 2024 financial results on Tuesday, August 13, 2024, after market close. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and business progress.

Investors and interested parties can access the live webcast and recorded replay through the investor relations section of GRAIL's website at investors.grail.com. Registration for the teleconference is available at https://grail-q2-financial-results-2024.open-exchange.net/. Participants are advised to register and join the webcast at least ten minutes before the scheduled start time to ensure timely connection.

GRAIL (Nasdaq: GRAL) has announced the enrollment of the first participant in the REACH study, evaluating the clinical impact of its Galleri® multi-cancer early detection (MCED) test in the Medicare population. The study, conducted at Community Health Network in Indiana, aims to enroll up to 50,000 Medicare beneficiaries across 50 sites, with a focus on including diverse and underrepresented populations.

The three-year study will compare participants receiving usual care plus an annual Galleri test to those receiving usual care alone. It will assess the reduction in diagnosed stage IV cancers, safety, and healthcare resource utilization associated with Galleri use. The study is FDA-approved and covered by Medicare for participants. This initiative addresses a critical need, as nearly 70% of cancer deaths in the US occur in people aged 65 and older.

GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England.

Results from the first 25,000 PATHFINDER 2 participants are expected in the second half of 2025, while final results from the NHS-Galleri trial are anticipated in 2026. These studies aim to expand GRAIL's clinical validation and performance evidence for the Galleri test, with a focus on diverse participant populations. The data will support GRAIL's premarket approval application to the FDA, which is currently in process under a Breakthrough Device Designation.